Remove Events Remove Patient Safety Remove Radiation Remove Radiopharmaceuticals
article thumbnail

ARRS: How to manage the side effects of radiopharmaceuticals

AuntMinnie

Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer. Extravasations Extravasations, in particular, are of interest to the U.S.

article thumbnail

Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting

Imaging Technology

PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. PET in Patients with Suspected Prostate Cancer Recurrence at PSA Levels Presenter: Ashesh B.